AlphAIAlphAI — Financial news for AI agents
SEC EDGARAUG 122 min read$PFE

BOURLA ALBERT purchased $1.0M of PFE

BOURLA ALBERT (Chairman & CEO) purchased 38,000 shares of PFIZER INC (PFE) at $26.34 ($1.00M total) on 2026-08-12.

Original reporting
SEC EDGAR · BOURLA ALBERT
Published Aug 12, 2026, 8:04 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 12, 2026, 8:09 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefInsider activity
Primary signal
$PFE
Neutral
medium confidence
Mentioned
$PFE
Relevance
7/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$PFENeutralLow
01

Why it matters

The newest fact is the CEO’s open-market purchase size, price, and total value. Traders may treat it as a small sentiment input, not a standalone catalyst.

02

Market read

A $1.0M CEO open-market buy is a modest, sentiment-oriented signal with limited direct implications for near-term fundamentals.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still does not disclose the insider’s rationale or whether other material company events are occurring concurrently.

Relevance 7/10Novelty 6/10Timing: filed 2026-08-12, after-hours SEC Form 4 disclosure

Background

The article is an SEC Form 4 insider transaction disclosure for Pfizer, filed on 2026-08-12.

Company-level read

Ticker impact

$PFENeutralMedium confidence
Context

Pfizer Form 4 shows CEO Albert Bourla bought 38,000 shares on 2026-08-12 at $26.34, totaling about $1.0M.

Expected impact

Likely limited near-term impact; any effect is more sentiment-driven than earnings or guidance-driven.

Evidence & confidence

The filing is primary-source and time-stamped, but the transaction is a single insider purchase without accompanying company guidance, contract, or regulatory development.

Market effects

Sector

Minimal; insider buying in a large pharma name typically does not reset sector expectations.

Regional

None indicated.

Global

None indicated.

Counterpoint

What could challenge this read

Insider buys can be routine, tax-related, or opportunistic around liquidity needs, and they do not guarantee near-term outperformance.

Key entities

  • issuer
    Pfizer Inc

    Subject of the Form 4 insider transaction disclosure.

  • insider
    Albert Bourla

    Chairman and CEO who purchased 38,000 shares on 2026-08-12.

Read at source← All news

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

PFE insider trading history →

Related articles

NOV 4
$PFEHighAI 8/10

International Business: Pfizer net profit up

Pfizer raised its full-year revenue forecast to $62-64bn and earnings to $2.95-$3.05 per share, citing strong demand for drugs like Padcev and Eliquis. CEO Albert Bourla attributed the increase to Q3 performance and confidence in the company's strategy. The company has invested heavily in acquisitions, including Seagen and Metsera, to drive growth. Analysts note that long-term success depends on experimental treatments in development.

gdnonline.com2 min
NOV 3
$PFEHighAI 9/10

Pfizer Inc. Q3 2026 Earnings Call Summary

Pfizer reported Q3 2026 earnings, highlighting 32% growth in launched and acquired products, including Seagen and Biohaven. The company raised full-year revenue guidance to $62-64B. Management projects high single-digit revenue CAGR from 2028-2033, driven by a strong pipeline. Pfizer also announced a $650M charge related to the Innovent transaction and aims for $2.5B in additional cost savings by 2029.

finance.yahoo.com2 min
NOV 3
$PFEHighAI 8/10

Pfizer (PFE) Q3 2026 Earnings Call Transcript

Pfizer (PFE) reported Q3 2026 revenue of $617 billion, up 7% operationally excluding COVID-19 products. Key growth drivers included Padcev, NURTEC, and Lorbrena. The company raised full-year revenue and EPS guidance, citing strong performance and pipeline progress. Pfizer also announced additional cost-saving initiatives. According to the company, strategic acquisitions and R&D investments are driving growth, with plans for multiple Phase 3 trials in 2026 and potential approvals in 2028.

finance.yahoo.com3 min
NOV 3
$PFEMed

Pfizer, fresh to China’s obesity market, looks to Viagra model to compete

Pfizer, partnering with Sciwind Biosciences, has launched Ecnoglutide, an obesity drug, in China. Pfizer CEO Albert Bourla compared the strategy to Viagra's success, noting the potential for out-of-pocket consumer purchases. The drug was acquired for $495 million, with Pfizer aiming to leverage its experience in self-pay markets. Pfizer also plans global expansion, focusing on berobenatide and other pipeline assets.

biospace.com2 min